John R. Weis

544 total citations
24 papers, 398 citations indexed

About

John R. Weis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John R. Weis has authored 24 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in John R. Weis's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Treatment and Pharmacology (3 papers). John R. Weis is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Treatment and Pharmacology (3 papers). John R. Weis collaborates with scholars based in United States, South Korea and Germany. John R. Weis's co-authors include George M. Rodgers, Robert E. Pitas, Brent D. Wilson, B. Sun, Ignacio Garrido‐Laguna, Kenneth M. Boucher, Kimberly McGregor, Shane Lloyd, Glynn Weldon Gilcrease and Mark Wade and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

John R. Weis

23 papers receiving 389 citations

Peers

John R. Weis

ONCOL

PRM

SURGE

Samira Syed United States

Seth Porter United States

E. E. Holdener Switzerland

Dava J. Garcia United States

M. Lind United Kingdom

Janet Fricker United Kingdom

G Gargano Italy

Joanna L. Sylman United States

Katsuyuki Kunieda Japan

Jordi Martínez-Serra Spain

Samira Syed United States

John R. Weis

151 ×1.1

ONCOL

122 ×1.1

55 ×0.8

PRM

41 ×0.7

SURGE

94 ×1.9

Citations per year, relative to John R. Weis John R. Weis (= 1×) peers Samira Syed

Countries citing papers authored by John R. Weis

Since Specialization

Citations

This map shows the geographic impact of John R. Weis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Weis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Weis more than expected).

Fields of papers citing papers by John R. Weis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Weis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Weis. The network helps show where John R. Weis may publish in the future.

Co-authorship network of co-authors of John R. Weis

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Weis. A scholar is included among the top collaborators of John R. Weis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Weis. John R. Weis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frank, Christina, Claire Jenkins, John R. Weis, et al.. (2025). Cholera due to exposure in Europe associated with consumption of holy water from Ethiopia, January to February 2025. Eurosurveillance. 30(14).

Kang, Yoon‐Koo, Min‐Hee Ryu, Yong Sang Hong, et al.. (2024). Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment. 56(3). 743–750. 1 indexed citations

Greenberg, Samantha, Wendy Kohlmann, Joanne Jeter, et al.. (2022). Discrepancies between tumor genomic profiling and germline genetic testing. ESMO Open. 7(4). 100526–100526. 10 indexed citations

Grossman, Kenneth, Wallace Akerley, Kenneth M. Boucher, et al.. (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer. 21(1). 510–510. 38 indexed citations

Lloyd, Shane, David Baraghoshi, Randa Tao, et al.. (2019). Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. American Journal of Clinical Oncology. 42(4). 355–362. 48 indexed citations

Gilcrease, Glynn Weldon, David D. Stenehjem, Mark Wade, et al.. (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Investigational New Drugs. 37(3). 482–489. 17 indexed citations

Buchmann, Luke, Marcus M. Monroe, Shane Lloyd, et al.. (2018). Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. Oral Oncology. 85. 1–7. 14 indexed citations

Cannon, Richard B., Dustin Boothe, Luke Buchmann, et al.. (2018). Academic Facility Utilization and Survival Outcomes in Adult Head and Neck Sarcomas: An NCDB Analysis. Otolaryngology. 159(3). 473–483. 19 indexed citations

Cavalieri, Courtney C., Eric A. Swanson, Jonathan Whisenant, et al.. (2017). Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.. Journal of Clinical Oncology. 35(4_suppl). 792–792. 5 indexed citations

10.

Stenehjem, David D., Sumati Gupta, Mark Wade, et al.. (2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies. Annals of Oncology. 27. vi367–vi367. 1 indexed citations

11.

Kang, Yoon‐Koo, Min‐Hee Ryu, Yong Sang Hong, et al.. (2016). A phase II study of apatinib, a highly selective inhibitor of VEGFR-2, in patients with metastatic solid tumors without standard treatment options. Annals of Oncology. 27. vi119–vi119. 6 indexed citations

12.

Garrido‐Laguna, Ignacio, Kimberly McGregor, Mark Wade, et al.. (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Investigational New Drugs. 31(5). 1257–1264. 56 indexed citations

13.

Gilcrease, Glynn Weldon, John R. Weis, Kimberly Jones, et al.. (2012). Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.. Journal of Clinical Oncology. 30(4_suppl). 600–600. 4 indexed citations

14.

Grossmann, Kenneth F., Wallace Akerley, Kenneth M. Boucher, et al.. (2011). Abstract 1308: A phase I clinical study investigating disulfiram and copper gluconate in patients with advanced treatment-refractory solid tumors involving the liver. Cancer Research. 71(8_Supplement). 1308–1308. 7 indexed citations

15.

Bair, Ryan J., John R. Weis, Frederic Clayton, Robert E. Glasgow, & David K. Gaffney. (2010). Palliative Chemoradiation in Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology. 28(15). e231–e232. 1 indexed citations

16.

Weis, John R., Yan-Li Gao, Thierry Conroy, et al.. (2007). Development of an EORTC module for the assessment of cancer related fatigue (EORTC FAR-15): Phase III results.. UCL Discovery (University College London). 1 indexed citations

17.

Weis, John R., et al.. (2004). Post‐transplant lymphoproliferative disorder limited to the skin. Journal of Cutaneous Pathology. 31(6). 453–457. 20 indexed citations

18.

Flechtner, Hans‐Henning, et al.. (2003). [Cancer fatigue syndrome].. PubMed. 55(1). 3–7. 1 indexed citations

19.

Weis, John R., et al.. (1991). Improved method of human umbilical arterial endothelial cell culture. Thrombosis Research. 61(2). 171–173. 47 indexed citations

20.

Weis, John R., Robert E. Pitas, Brent D. Wilson, & George M. Rodgers. (1991). Oxidized low‐density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation ¹. The FASEB Journal. 5(10). 2459–2465. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact